Schedule 13G ownership disclosure

Black Diamond Therapeutics Inc

Common Stock · CUSIP: 09203E105

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BB Biotech AG

    Shares: 8,517,839.00 · Class: 15.1%

  • Biotech Growth N.V.

    Shares: 8,517,839.00 · Class: 15.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-013934
Form type
SCHEDULE 13G/A
Filer
BB BIOTECH AG
CIK
CIK 924223
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub